Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCHR1 | Q99705 | 13/20 | 0.51 |
| ▸ | HTR2A | P28223 | 1/20 | 0.50 |
| ▸ | HTR2C | P28335 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | PNMT | P11086 | 1/20 | 0.41 |
| ▸ | ASIC3 | Q9UHC3 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21088048 | 0.88 | MCHR1 (0.53) | MCHR1HTR2AHTR2CKDM4EALOX15 | |
| SCHEMBL18404827 | 0.84 | MCHR1 (0.52) | MCHR1HTR2AHTR2CKDM4EALOX15 | |
| SCHEMBL16477202 | 0.83 | MCHR1 (0.51) | MCHR1 | |
| SCHEMBL16610030 | 0.82 | MCHR1 (0.51) | MCHR1HTR2AHTR2CKDM4EALOX15 | |
| Hydrochloric Acid SCHEMBL17940522 | 0.81 | KDM4E (0.51) | MCHR1HTR2AHTR2CKDM4EALOX15 | |
| SCHEMBL20884616 | 0.80 | MCHR1 (0.49) | MCHR1HTR2AHTR2CKDM4EALOX15 | |
| SCHEMBL20883916 | 0.80 | MCHR1 (0.50) | MCHR1HTR2AHTR2CKDM4EALOX15 | |
| SCHEMBL967629 | 0.78 | HTR2C (0.79) | MCHR1HTR2AHTR2CKDM4EALOX15 | |
| SCHEMBL9966179 | 0.78 | ALOX5 (0.53) | HTR2AHTR2CKDM4EALOX15MAPK1 | |
| Trifluoroacetic Acid SCHEMBL29984059 | 0.78 | MCHR1 (0.50) | MCHR1HTR2AHTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170204095-A1 | (1-AZINONE)-SUBSTITUTED PYRIDOINDOLES | APOLLO ADMINISTRATIVE AGENCY LLC, AS SUCCESSOR AGENT | 2017-07-20 | — | — | US | disclosed |
| US-20170204095-A1 | (1-AZINONE)-SUBSTITUTED PYRIDOINDOLES | APOLLO ADMINISTRATIVE AGENCY LLC, AS SUCCESSOR AGENT | 2017-07-20 | — | — | US | disclosed |
| US-20170204095-A1 | (1-AZINONE)-SUBSTITUTED PYRIDOINDOLES | APOLLO ADMINISTRATIVE AGENCY LLC, AS SUCCESSOR AGENT | 2017-07-20 | — | — | US | disclosed |
| US-9650378-B2 | (1-azinone)-substituted pyridoindoles | ALBANY MOLECULAR RESEARCH, INC. (US) | 2017-05-16 | — | — | US | disclosed |
| US-9650378-B2 | (1-azinone)-substituted pyridoindoles | ALBANY MOLECULAR RESEARCH, INC. (US) | 2017-05-16 | — | — | US | disclosed |
| US-9650378-B2 | (1-azinone)-substituted pyridoindoles | ALBANY MOLECULAR RESEARCH, INC. (US) | 2017-05-16 | — | — | US | disclosed |
| US-20160159798-A1 | (1-AZINONE)-SUBSTITUTED PYRIDOINDOLES | HARMONY BIOSCIENCES, LLC | 2016-06-09 | — | — | US | disclosed |
| US-20160159798-A1 | (1-AZINONE)-SUBSTITUTED PYRIDOINDOLES | HARMONY BIOSCIENCES, LLC | 2016-06-09 | — | — | US | disclosed |
| US-20160159798-A1 | (1-AZINONE)-SUBSTITUTED PYRIDOINDOLES | HARMONY BIOSCIENCES, LLC | 2016-06-09 | — | — | US | disclosed |
| US-9296743-B2 | (1-azinone)-substituted pyridoindoles | ALBANY MOLECULAR RESEARCH, INC. (US) | 2016-03-29 | — | — | US | disclosed |
| US-8716308-B2 | (1-azinone)-substituted pyridoindoles | ALBANY MOLECULAR RESEARCH, INC. (US) | 2014-05-06 | — | — | US | disclosed |
| EP-2476680-A1 | (1-Azinone)-Substituted Pyridoindoles | Albany Molecular Research, Inc. (US) | 2012-07-18 | — | — | EP | disclosed |
| EP-2476680-A1 | (1-Azinone)-Substituted Pyridoindoles | Albany Molecular Research, Inc. (US) | 2012-07-18 | — | — | EP | disclosed |
| US-20100331339-A9 | (1-AZINONE)-SUBSTITUTED PYRIDOINDOLES | ALBANY MOLECULAR RESEARCH, INC. (US) | 2010-12-30 | — | — | US | disclosed |
| US-20100331339-A9 | (1-AZINONE)-SUBSTITUTED PYRIDOINDOLES | ALBANY MOLECULAR RESEARCH, INC. (US) | 2010-12-30 | — | — | US | disclosed |
| US-20100331339-A9 | (1-AZINONE)-SUBSTITUTED PYRIDOINDOLES | ALBANY MOLECULAR RESEARCH, INC. (US) | 2010-12-30 | — | — | US | disclosed |
| US-20090275590-A1 | (1-AZINONE)-SUBSTITUTED PYRIDOINDOLES | ALBANY MOLECULAR RESEARCH, INC. (US) | 2009-11-05 | — | — | US | disclosed |
| US-20090275590-A1 | (1-AZINONE)-SUBSTITUTED PYRIDOINDOLES | ALBANY MOLECULAR RESEARCH, INC. (US) | 2009-11-05 | — | — | US | disclosed |
| US-20090275590-A1 | (1-AZINONE)-SUBSTITUTED PYRIDOINDOLES | ALBANY MOLECULAR RESEARCH, INC. (US) | 2009-11-05 | — | — | US | disclosed |
| WO-2009089482-A1 | (1-AZINONE) -SUBSTITUTED PYRIDOINDOLES AS MCH ANTAGONISTS | ALBANY MOLECULAR RESEARCH, INC. (US) | 2009-07-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100331339-A9 | (1-AZINONE)-SUBSTITUTED PYRIDOINDOLES | NR3C2, NR0B1, NR3C1 | MCHR1 411/4885HTR2A 1612/4885HTR2C 780/4885 |
| US-20170204095-A1 | (1-AZINONE)-SUBSTITUTED PYRIDOINDOLES | NR3C2, NR2E3, NR0B1 | MCHR1 399/4885HTR2A 1688/4885HTR2C 825/4885 |
| US-20090275590-A1 | (1-AZINONE)-SUBSTITUTED PYRIDOINDOLES | NR3C2, NR0B1, NR3C1 | MCHR1 411/4885HTR2A 1612/4885HTR2C 780/4885 |
| US-20160159798-A1 | (1-AZINONE)-SUBSTITUTED PYRIDOINDOLES | NR3C2, NR2E3, NR0B1 | MCHR1 399/4885HTR2A 1688/4885HTR2C 825/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.